Galactooligosaccharide fibres exert immunomodulatory properties and interfere with riboflavin derivatives in an ex-vivo study
Galactooligosaccharide fibres exert immunomodulatory properties and interfere with riboflavin derivatives in an ex-vivo study
Mucosal-associated invariant T (MAIT) cells are T lymphocytes with a key role in immune surveillance. Riboflavin derivatives produced by the gut microbiota are MAIT cell ligands(Reference Patel, Kjer-Nielsen and Le Nours1). Evidence suggests that unknown metabolites synthesised by probiotic strains modulate MAIT cell function(Reference Johansson, Bjorkander and Mata Forsberg2,Reference Hinks3) . Galactooligosaccharides (GOS) are prebiotics produced via transgalactosylation by β-galactosidases, which are expressed by gut bacteria(Reference Grimaldi, Swann and Vulevic4). We aim to assess whether GOS modulate the function of MAIT cells or other peripheral blood mononuclear cell (PBMC) subsets and whether cells respond differently to a riboflavin derivative in presence of GOS.
Healthy PBMCs (n = 8) were cultured for 20 h with GOS (Bimuno®) (12 mg/mL), or a riboflavin derivative (5-A-RU 0.18 μM + methylglyoxal 1 μM), or co-stimulated with both. Unstimulated cells were used as control. One-way ANOVA or Kruskal-Wallis test followed by Bonferroni's or Dunn's post-hoc test were performed depending upon data distribution.
Treatment with GOS did not affect viability. PBMCs incubated with GOS presented lower CD4 expression on T helper cells (MFI 14,561 ± 612.3 vs 17,593 ± 2,157; p = 0.0053) and secreted more IL-8 (104.0 ± 62.9 ng/mL vs 3.8 ± 2.6 ng/mL; p = 0.0005) compared to control. Intracellular staining revealed that monocytes were responsible for the upregulated IL-8 expression. Co-treatment of cells with the riboflavin derivative and GOS resulted in decreased CD69 expression by lymphocytes (MFI 19,076 ± 2,648 vs 15,761 ± 1,158 p = 0.0017), T cells (MFI 20,317 ± 2,303 vs 16,572 ± 1,439 p < 0.0001) and cytotoxic T cells (MFI 24,669 ± 4,249 vs 20,188 ± 3,485 p = 0.0205) compared to riboflavin derivative alone, and in lower % MAIT cells expressing IL-17A vs riboflavin derivative alone (0.03 ± 0.03 vs 0.49 ± 0.40 p = 0.0008).
Overall, GOS showed immunomodulatory effects, including the modulation of CD4 expression and enhancement of IL-8 secretion. PBMCs responded differently to ligand challenge in presence of GOS, suggesting that the prebiotic may interfere with riboflavin metabolites or signal via similar pathways.
Del Fabbro, S.
5a48993c-a34b-4aff-92fc-65b94df566d5
Calder, P.C.
532478ab-6402-49af-b4ba-97930b2a354b
Childs, C.E.
90fcaaa5-f178-4689-a602-b0588553009f
27 October 2021
Del Fabbro, S.
5a48993c-a34b-4aff-92fc-65b94df566d5
Calder, P.C.
532478ab-6402-49af-b4ba-97930b2a354b
Childs, C.E.
90fcaaa5-f178-4689-a602-b0588553009f
Del Fabbro, S., Calder, P.C. and Childs, C.E.
(2021)
Galactooligosaccharide fibres exert immunomodulatory properties and interfere with riboflavin derivatives in an ex-vivo study.
Proceedings of the Nutrition Society, 80 (OCE5).
(doi:10.1017/S0029665121003207).
Abstract
Mucosal-associated invariant T (MAIT) cells are T lymphocytes with a key role in immune surveillance. Riboflavin derivatives produced by the gut microbiota are MAIT cell ligands(Reference Patel, Kjer-Nielsen and Le Nours1). Evidence suggests that unknown metabolites synthesised by probiotic strains modulate MAIT cell function(Reference Johansson, Bjorkander and Mata Forsberg2,Reference Hinks3) . Galactooligosaccharides (GOS) are prebiotics produced via transgalactosylation by β-galactosidases, which are expressed by gut bacteria(Reference Grimaldi, Swann and Vulevic4). We aim to assess whether GOS modulate the function of MAIT cells or other peripheral blood mononuclear cell (PBMC) subsets and whether cells respond differently to a riboflavin derivative in presence of GOS.
Healthy PBMCs (n = 8) were cultured for 20 h with GOS (Bimuno®) (12 mg/mL), or a riboflavin derivative (5-A-RU 0.18 μM + methylglyoxal 1 μM), or co-stimulated with both. Unstimulated cells were used as control. One-way ANOVA or Kruskal-Wallis test followed by Bonferroni's or Dunn's post-hoc test were performed depending upon data distribution.
Treatment with GOS did not affect viability. PBMCs incubated with GOS presented lower CD4 expression on T helper cells (MFI 14,561 ± 612.3 vs 17,593 ± 2,157; p = 0.0053) and secreted more IL-8 (104.0 ± 62.9 ng/mL vs 3.8 ± 2.6 ng/mL; p = 0.0005) compared to control. Intracellular staining revealed that monocytes were responsible for the upregulated IL-8 expression. Co-treatment of cells with the riboflavin derivative and GOS resulted in decreased CD69 expression by lymphocytes (MFI 19,076 ± 2,648 vs 15,761 ± 1,158 p = 0.0017), T cells (MFI 20,317 ± 2,303 vs 16,572 ± 1,439 p < 0.0001) and cytotoxic T cells (MFI 24,669 ± 4,249 vs 20,188 ± 3,485 p = 0.0205) compared to riboflavin derivative alone, and in lower % MAIT cells expressing IL-17A vs riboflavin derivative alone (0.03 ± 0.03 vs 0.49 ± 0.40 p = 0.0008).
Overall, GOS showed immunomodulatory effects, including the modulation of CD4 expression and enhancement of IL-8 secretion. PBMCs responded differently to ligand challenge in presence of GOS, suggesting that the prebiotic may interfere with riboflavin metabolites or signal via similar pathways.
This record has no associated files available for download.
More information
Published date: 27 October 2021
Identifiers
Local EPrints ID: 476696
URI: http://eprints.soton.ac.uk/id/eprint/476696
ISSN: 0029-6651
PURE UUID: 763664b1-9428-4827-9353-cb275ede0035
Catalogue record
Date deposited: 11 May 2023 16:46
Last modified: 17 Mar 2024 01:16
Export record
Altmetrics
Contributors
Author:
S. Del Fabbro
Author:
P.C. Calder
Author:
C.E. Childs
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics